Immune response to hepatitis B vaccination in HIV-positive adults with isolated antibodies to HBV core antigen.

Détails

ID Serval
serval:BIB_7D286B3CF16D
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Immune response to hepatitis B vaccination in HIV-positive adults with isolated antibodies to HBV core antigen.
Périodique
Journal of Infection
Auteur(s)
Kaech C., Pache I., Bürgisser P., Elzi L., Darling K.E., Cavassini M.
ISSN
1532-2742 (Electronic)
ISSN-L
0163-4453
Statut éditorial
Publié
Date de publication
2012
Volume
65
Numéro
2
Pages
157-164
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov'tPublication Status: ppublish
Résumé
OBJECTIVE: To investigate the merits of vaccination against hepatitis B virus (HBV) in HIV-positive individuals with isolated antibodies to hepatitis B core antigen (anti-HBc).
METHODS: HIV-positive patients with isolated anti-HBc and CD4 counts >200 cells/mm(3) received HBV vaccination. An antibody titre to hepatitis B surface antigen (anti-HBs titres) ≥10 IU/L one month post-vaccination was termed an anamnestic response; a titre <10 IU/L was termed a primary response. Patients with primary responses received a 3-dose vaccine course. Anti-HBs titres in all responders were measured 12 and 24 months post-vaccination.
RESULTS: 37 patients were studied: 19 (51%) were co-infected with hepatitis C; median CD4 count was 443 cells/mm(3). 8/37 patients (22%) elicited an anamnestic response. 29/37 patients (78%) elicited a primary response. After a 3-dose vaccine course, 15/25 primary responders (60%) achieved anti-HBs titres ≥10 IU/L. HIV acquisition through injecting drug use was the only independent predictor of an anamnestic response (OR 22.9, CI 1.71-306.74, P=0.018). Median anti-HBs titres for anamnestic and primary responders were 51 IU/L (13-127) and 157 IU/L (25-650) respectively. Of all responders, 12/23 (52%) retained anti-HBs titres ≥10 IU/L at 24 months. Anti-HBs duration was not significantly different between anamnestic and primary responders.
CONCLUSIONS: 23/37 HIV-positive patients (62%) with isolated anti-HBc achieved anti-HBs titres ≥10 IU/L after 1-3 vaccine doses. However, duration of this immune response was short-lived (<two years) in over half the responders. The implications regarding re-infection risk in this population are yet to be determined.
Mots-clé
Adult, CD4 Lymphocyte Count, Female, HIV Infections/immunology, Hepatitis B Antibodies/blood, Hepatitis B Core Antigens/immunology, Hepatitis B Surface Antigens/immunology, Hepatitis B Vaccines/administration & dosage, Hepatitis B Vaccines/immunology, Humans, Male, Middle Aged, Time Factors
Pubmed
Web of science
Création de la notice
23/07/2012 9:37
Dernière modification de la notice
09/04/2020 5:20
Données d'usage